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Abstract
T-lymphocytes and B-lymphocytes are key players in allergic asthma, with B-lymphocytes producing antigen-specific
immunoglobulins E (IgE). We used a mouse model of chemical-induced asthma and transferred B-lymphocytes from
sensitized animals into naïve wild type mice, B-lymphocyte knock-out (B-KO) mice or severe combined
immunodeficiency (SCID) mice. On days 1 and 8, BALB/c mice were dermally sensitized with 0.3% toluene
diisocyanate (TDI) (20µl/ear). On day 15, mice were euthanized and the auricular lymph nodes isolated. B-
lymphocytes (CD19+) were separated from the whole cell suspension and 175,000 cells were injected in the tail vein
of naïve wild type, B-KO or SCID mice. Three days later, the mice received a single oropharyngeal challenge with
0.01% TDI (20µl) or vehicle (acetone/olive oil (AOO)) (controls). Airway reactivity to methacholine and total and
differential cell counts in the bronchoalveolar lavage (BAL) fluid were measured 24 hours after challenge. B-
lymphocytes of AOO or TDI-sensitized mice were characterized for the expression of surface markers and production
of cytokines. We found that transfer of B-cells obtained from mice dermally sensitized to toluene diisocyanate (TDI)
into naïve wild type mice, B-KO mice or SCID mice led, within three days, to an acute asthma-like phenotype after an
airway challenge with TDI. This response was specific and independent of IgE. These B-lymphocytes showed
antigen presenting capacities (CD80/CD86 and CD40) and consisted of B effector (Be)2- (IL-4) and Be1-lymphocytes
(IFN-γ). The transferred B-lymphocytes were visualized near large airways, 24 hours after TDI challenge. Thus, B-
lymphocytes can provoke an asthmatic response without the action of T-lymphocytes and without major involvement
of IgE.
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Introduction
Many studies have demonstrated a crucial role for T-
lymphocytes and the cytokines they produce in the
development of allergic asthma [1]. In contrast, the exact role
of B-lymphocytes in the development of asthma has been less
well investigated [2], except for the well-known ability of B-
lymphocytes to produce antigen-specific IgE antibodies after
having been induced by Th2 cells to do so [3]. However, not all
asthma is allergic (or atopic) asthma, and in a substantial
proportion of asthmatics there seems to be little or no
implication of specific IgE in the pathogenesis of the disease
[4]. This is most notably the case in immunologically mediated
occupational asthma (OA) caused by some sensitizing
chemicals, such as diisocyanates [5]. Diisocyanates are low
molecular weight chemicals widely used in industry for the
production of e.g. polyurethane foams, vanish, paint, and
isolation material [6,7]. They are an important cause of
occupational asthma [5]. While high molecular weight agents,
such as flour latex, enzymes, etc, can cause occupational
asthma via the classical IgE mechanisms, sensitization to low-
molecular-weight chemicals results from a response of the
immune system to haptens conjugated with endogenous
proteins. However, the exact pathways and mechanisms of
sensitization to such chemicals and the pathogenesis of the
subsequent respiratory reactions are much less well
understood, as they seem to differ from those of the classic
IgE-mediated asthma [8]. Lavaud et al. showed that showed
that treatment of patients with severe occupational asthma due
to low molecular weight agents, with the anti-IgE antibody
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omalizumab lowered the levels of total serum IgE and in most
cases improved FEV1, but did not result in complete controlled
asthma [9].
Recently, the pathophysiology of B-lymphocytes has
received more interest and a number of new functions of B-
lymphocytes have been identified, beyond the production of
immunoglobulins. Clinical data show that B-lymphocyte
depletion is an effective therapy for several T cell-mediated
autoimmune diseases [10]. Lindell et al. showed that in asthma
caused by cockroach allergen, B-lymphocytes also contribute
to chronic allergic lung disease, possibly through antigen
presentation, via promoting Th2 responses [2]. In addition,
Harris et al. showed that B-lymphocytes can be subdivided into
two subsets of effector B-lymphocytes (Be1 and Be2)
depending on the cytokines they produce. Be1-lymphocytes
(producing IFN-γ) regulate the differentiation of naïve Th-
lymphocytes to Th1-lymphocytes, while Be2-lymphocytes
(producing IL-4) regulate the differentiation to Th2-lymphocytes
[11].
Our research group developed a robust mouse model for
immunologically mediated chemical-induced asthma using a
prototypical occupational asthmogen toluene diisocyanate
(TDI) [12–20]. Because we were intrigued by the conundrum
that isocyanate-induced asthma has many features of allergic
asthma, both in humans and in mouse models, and yet does
not appear to depend on the presence of (humoral) IgE
antibodies in our model, we set out to investigate the role, if
any, of B-lymphocytes in our mouse model. To achieve this, we
characterized the profile of B-lymphocytes after dermal
sensitization to TDI, on the one hand, and we performed
adoptive transfer experiments using physiologically relevant
amounts (175,000) of B-lymphocytes obtained from TDI-
sensitized mice into naïve wild type mice, B-KO mice and
severe combined immunodeficiency (SCID), which are mice
deficient in T- and B-lymphocytes.
We found that B-lymphocytes may play an important primary
role in asthma, without help from T-lymphocytes.
Materials and Methods
Reagents
Toluene-2,4-diisocyanate (98 %; Fluka, CAS 584-84-9),
trimellitic anhydride (97 %, CAS 552-30-7), acetyl-β-
methylcholine (methacholine), acetone, phorbol myristate
acetate (PMA, CAS 16561-29-8) and Ca2+ ionophore (CAS
56092-82-1) were obtained from Sigma-Aldrich (Bornem,
Belgium). Pentobarbital (Nembutal®) was obtained from Sanofi
Santé Animale (CEVA, Brussels, Belgium) and Isoflurane
(Forene®) from Abbott Laboratories (S.A. Abbott N.V.,
Ottignies, Belgium). The vehicle (acetone/olive oil, AOO) used
to dissolve TDI consisted of a mixture of 2 volumes of acetone
and 3 volumes of olive oil (Selection de Almazara, Carbonell,
Madrid, Spain) for the dermal sensitization, and 1 volume of
acetone and 4 volumes of olive oil for the oropharyngeal
challenge. Concentrations of TDI are given as percent (v/v) in
AOO, while TMA concentrations are given as percent (w/v).
Animals
Male wild type BALB/c mice were obtained from Harlan
(Horst, The Netherlands). Male Jh mice (BALB/c background),
which are deficient in B-lymphocytes (labeled as B-KO mice,
hereafter) and C.B-17 SCID mice (BALB/c background), which
are deficient in T-lymphocytes and B-lymphocytes, were
obtained from Taconic (Ejby, Denmark). All mice were
approximately 20 g and 6 weeks old. The mice were housed in
a conventional animal house in filter top cages with 12-h dark/
light cycles and received lightly acidified water and pelleted
food (Trouw Nutrition, Gent, Belgium) ad libitum.
Experimental setup
All experimental procedures were approved by the KU
Leuven Ethical Committee for Animal Experiments.
The experimental protocols were based on our previously
published protocol of chemical-induced asthma in which mice
are first sensitized by receiving dermal applications of the test
chemical on days 1 and 8 and then challenged via the airways
with a lower concentration of the test chemical on day 15, with
the responses (airway reactivity to methacholine, lung
inflammation, immunologic readouts) being assessed 24 hours
after challenge [14,19,20].
This complete protocol was applied in B-KO mice: on days 1
and 8, B-KO mice received dermal applications of 0.3 % TDI or
vehicle (AOO) on the dorsum of both ears (20 µl/ear). On day
15, they received an oropharyngeal challenge with 0.01% TDI
or vehicle [19]. Each treatment group consisted of 8 to 9
animals. Mice were euthanized 24 hours after the challenge, by
intraperitoneal injection of pentobarbital (90 mg/kg).
In the adoptive transfer experiments, a similar protocol was
used, except for the fact that sensitization and challenge
portions took place in donor (D) and recipient (R) mice,
respectively, with the cells (or serum) being obtained and
transferred on day 15 and the challenge being done 3 days
later.
Thus, on days 1 and 8, the donor (D) animals received
dermal applications of 0.3 % TDI, 5 % trimellitic anhydride
(TMA) or the vehicle (20 µl/ear). On day 15, these mice were
euthanized, auricular lymph nodes were pooled and the spleen
was dissected. Cell suspensions were obtained by pressing the
lymph nodes or spleen through a cell strainer (100 µm) (BD
Biosciences, Erembodegem, Belgium) and rinsing with 10 ml
buffer (MACS BSA Stock solution diluted 1:20 with autoMACS
Rinsing Solution (Miltenyi Biotec, Utrecht, The Netherlands)).
Cells were centrifuged (1000 g, 4 °C, 10 min) and counted
using a Bürker hemocytometer. CD19+ B-lymphocytes were
isolated with CD19+ microbeads (Miltenyi Biotec) according to
manufacturer’s instructions, using pre-separation filters, LS
columns and the QuadroMACS (Miltenyi Biotec). CD19+ B-
lymphocytes or lymph node cells without B-lymphocytes were
resuspended in HBSS- buffer (Invitrogen, Merelbeke, Belgium)
and 175,000 cells or 325,000 cells, respectively, were injected,
in a total volume of 250 µl, intravenously in the tail vein of naïve
recipient (R) mice. In a separate experiment, on day 15, mice
were euthanized and blood was obtained via the retro-orbital
plexus. The blood was centrifuged (14,000 g, 10 min) and 100
µl serum (D1: 1537 ± 702 ng/ml IgE as described in [21]) in a
B-lymphocytes in chemical-induced asthma
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total volume of 250 µl (dissolved in HBSS-) were transferred in
naïve wild type BALB/c mice.
Three days after the transfer of B-lymphocytes, lymph node
cells without B-lymphocytes or serum, recipient mice received
an oropharyngeal challenge with 0.01 % TDI, 0.05 % TMA or
vehicle. Each treatment group consisted of 3 to 10 animals.
Mice were euthanized 24 hours after the challenge.
Experimental groups are labeled as follows: DTDIRVeh,
DTDIRTDI, DTMARTMA, DTMARVeh and DTDIRTMA, with D indicating the
dermal treatment (sensitization) received by donor (D) animals
on days 1 and 8, i.e. either TDI (DTDI) or TMA (DTMA), and R
indicating the type of challenge received by the naïve recipient
(R) animals three days after having received the B-
lymphocytes, i.e. vehicle (RVeh), TDI (RTDI) or TMA (RTMA).
Airway hyperreactivity (AHR)
Twenty four hours after the challenge, reactivity to
methacholine was assessed invasively using a forced
oscillation technique (FlexiVent, SCIREQ, Montreal, Canada)
[22]. As previously described, airway resistance (R) was
measured using a “snapshot” protocol. For each mouse, R was
plotted against methacholine concentration (0 mg/ml tot 10
mg/ml) and the AUC was calculated to perform statistical
analysis [22].
Bronchoalveolar lavage and lung histology
After measuring AHR, mice were deeply anesthetized by an
intraperitoneal injection of pentobarbital (90 mg/kg body
weight). Blood was taken from the retro-orbital plexus,
centrifuged (14000 g, 10 min) and serum samples were stored
for further analyses. The lungs were lavaged, in situ, three
times with 0.7 ml sterile saline (0.9 % NaCl), and the recovered
fluid was pooled. Cells were counted using a Bürker
hemocytometer (total cells) and the BAL fluid was centrifuged
(1000 g, 10 min). For differential cell counts, 250 µl of the
resuspended cells (100,000 cells/ml) were spun (300 g, 6 min)
(Cytospin 3, Shandon, TechGen, Zellik, Belgium) onto
microscope slides, air-dried and stained (Diff-Quik® method,
Medical Diagnostics, Düdingen, Germany). For each sample,
200 cells were counted for the number of macrophages,
eosinophils, neutrophils and lymphocytes.
After BAL fluid collection, the lungs were instilled with 4%
formaldehyde until full inflation of all lobes, as judged visually.
Evaluation of lung injury on slides stained by hematoxylin and
eosin was performed by an experienced pathologist who was
blinded to the treatment given to the mice (AxioPlan
microscope, objective Pan-Apochromat x40 with numeral
aperture 0.95, Carl Zeiss, Zaventem, Belgium). Pictures were
taken with an AxioCam HRc camera and acquisition was
performed with AxioVision software 4.8 (Carl Zeiss, Zaventem,
Belgium).
Total serum IgE
The OptEIA Mouse IgE set from Pharmingen
(BDBiosciences) was used to measure total serum IgE (diluted
1/70). Measurements were performed according to the
manufacturer’s instructions.
Surface marker expression on B-lymphocytes
On day 15, wild type BALB/c mice dermally sensitized with
TDI (or AOO) were euthanized and auricular lymph nodes were
dissected and cell suspensions were obtained as described
above. 500,000 cells were stained with anti-CD19 (PerCP-
Cy5.5, BD Biosciences, Erembodegem, Belgium), anti-major
histocompatibility complex II (MHCII, PE), anti-IgD (PE), anti-
CD23 (FITC), anti-CD5 (FITC), anti-CD40 (FITC), anti-CD86
(PE) and anti-CD80 (PE) labeled antibodies, according to
standard procedures, and with control samples being labelled
with isotype match control antibodies (BD Biosciences,
Erembodegem, Belgium). Flow cytometry (FACS Calibur, BD
Biosciences, Erembodegem, Belgium) was performed using at
least 105 cells.
Intracellular cytokine staining
On day 15, wild type BALB/c mice sensitized with TDI or
AOO were euthanized and auricular lymph nodes were
dissected and cell suspensions were obtained as described
above. Intracellular cytokine staining was performed according
to manufacturer’s instructions (BD Biosciences, Erembodegem,
Belgium). Briefly, lymphocytes were restimulated in vitro with
PMA (5 ng/ml) and Ca2+ ionophore (500 ng/ml). BD
GolgiStopTM containing monensin (BD Biosciences,
Erembodegem, Belgium) was added one hour after the culture
was initiated. Lymphocytes were collected 5 hours later and
stained for anti-CD19 surface marker (APC-Cy7). Afterwards,
cells were fixed and permeabilized, and incubated with anti-
IFN-γ (PE-Cy7), anti-IL-4 (APC) and anti-IL-10 (PE) labeled
antibodies. Flow cytometry (FacsArray, BD Biosciences,
Erembodegem, Belgium) was performed using at least 105
cells.
B-cell homing study with SNARF-1 labeling
On day 15, wild type BALB/c mice sensitized with TDI were
euthanized; auricular lymph nodes were dissected and B-
lymphocytes were isolated as mentioned above. Freshly
isolated B-lymphocytes were incubated in PBS- (Invitrogen,
Merelbeke, Belgium) with 125 nM of the succinimidyl ester of
SNARF-1 carboxylic acid acetate (Invitrogen, Merelbeke,
Belgium) for 15 minutes at 37 °C. Afterwards, the cells were
washed twice with RPMI-1640 medium and resuspended in
HBSS- to be transferred into naïve wild type BALB/c mice.
5x106 labeled B-lymphocytes were transferred. Three days
after transferring the labeled B-lymphocytes, mice were
challenged with 0.01 % TDI or vehicle and 24 hours later lungs
were dissected after perfusion of the mice with NaCl. The
distribution of transferred B-lymphocytes was investigated
using fluorescence microscopy (Olympus BX61, objective x40
oil with numeral aperture 1.30) on cryostat sections (sagittal
axis, 10 µm sections) of the lung mounted in ProLong® Gold
antifade reagent with DAPI (Invitrogen, Merelbeke, Belgium).
Photographs were taken with a digital color camera UC30
3Mpixel (Olympus, Aartselaar, Belgium) and acquisition was
performed with Cell F Software (Olympus, Aarstselaar,
Belgium).
B-lymphocytes in chemical-induced asthma
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Statistical analysis
Normality of distribution of the data was assessed by the
D’Agostino & Pearson omnibus normality test. All data are
presented as means or means and SEM. AHR and the surface
markers were analyzed using an unpaired t-test, whereas the
airway inflammation and the intracellular cytokine stainings
were analyzed using a nonparametric Mann-Whitney test
(Graphpad Prism 4.01, Graphpad Software Inc, San Diego,
USA). A level of p < 0.05 (two tailed) was considered
significant.
Results
Characterization of B-lymphocytes and serum from
donor mice
Blood was collected from vehicle and TDI-treated mice.
Figure 1 F shows significantly increased levels of total serum
IgE in TDI-sensitized mice compared to vehicle treated mice.
We characterized the B-lymphocytes isolated from the
auricular lymph nodes of TDI or vehicle treated mice (Figure 1).
On the basis of different surface markers we distinguished
several B-lymphocyte subpopulations. Sensitization with TDI
resulted in a significantly increased number of follicular B-
lymphocytes (CD23+IgD+CD19+) (Figure 1 A) as well as
increases in CD5+ B-lymphocytes (B1a) and CD5- B-
lymphocytes (B1b and B2) (Figure 1 B) in the auricular lymph
nodes. All B-lymphocytes expressed MHCII, independently of
TDI or AOO treatment. Co-stimulatory molecules CD86, CD80
(activation of T-lymphocytes) and CD40 (activation of B-
lymphocytes) were upregulated in B-lymphocytes from TDI-
treated mice (DTDI) compared to control vehicle-treated mice
(DVeh) (Figure 1 C).
Cytokine production was assessed by stimulating cultured
lymph node cells for 5 hours with PMA and Ca2+ ionophore in
the presence of monensin. CD19+ B-lymphocytes from TDI-
sensitized mice thus produced significantly higher levels of
IL-4, IFN-γ and IL-10 than B-lymphocytes from AOO-treated
mice (Figure 1 E). The FACS plots (Figure 1 D) showed a
mixed B effector (Be)1 (IFN-γ) - Be2 (IL-4) response.
Adoptive transfer experiments into naïve wild type
BALB/c mice
Freshly isolated B-lymphocytes were transferred into naïve
wild type BALB/c mice in order to assess the specific role of B-
lymphocytes (Figure 2).
In a first series, B-lymphocytes were isolated from the
auricular lymph nodes of TDI-sensitized wild type BALB/c mice
and then transferred into naïve wild type BALB/c mice. Three
days later, the mice were challenged with TDI and this resulted
in an increase in airway reactivity (Figure 2 A) and airway
inflammation (Figure 2 B), but not in total serum IgE levels, 24h
later (Figure 2 -C). Histology revealed an influx of
polymorphonuclear leukocytes and epithelial damage in the
DTDIRTDI group (Figure 2 D). We also transferred the reciprocal
lymphocyte population (without B-lymphocytes) into naïve
mice, but this did not alter airway reactivity or produce airway
inflammation after TDI challenge compared to their control
mice (data not shown).
In a second series of experiments, we assessed the
specificity of the B-lymphocytes for TDI. Here, we show that
transferring B-lymphocytes from trimellitic anhydride (TMA),
another known potent chemical respiratory sensitizer, mice into
naive mice, followed by a TMA challenge 3 days later results in
AHR (Figure 2 E) and airway inflammation (data not shown),
indicating that the transfer model also works with other
chemical sensitizers. Next, mice that received B-lymphocytes
obtained from TDI-sensitized mice were challenged with
trimellitic anhydride (TMA). This yielded no increase in AHR
(Figure 2 F) and no airway inflammation (data not shown),
indicating that the responses with TDI sensitization followed by
TDI challenge were indeed linked to recognition of TDI by the
B-lymphocytes.
In a third series, the involvement of immunoglobulins
possibly secreted by the transferred B-lymphocytes was
explored. Transferring serum obtained from TDI-sensitized
mice into naïve mice followed by a TDI challenge resulted in
limited airway inflammation (data not shown) and a less
pronounced, although significant, airway hyperreactivity (AHR)
after TDI challenge (Figure 2 G).
Finally, B-lymphocytes isolated from the spleen of TDI-
sensitized mice and transferred into naïve wild type BALB/c
mice induced AHR (Figure 2 H) after challenging the mice with
TDI, but no significant lung inflammation was found (data not
shown).
Adoptive transfer experiments into naïve immune-
compromised BALB/c mice
B-KO mice were used to confirm a role for B-lymphocytes in
chemical-induced asthma.
First, our mouse model using two dermal applications of TDI
and one oropharyngeal challenge with TDI was tested in the B-
KO mice. In these animals (as well as in appropriate controls),
AHR remained low, no airway inflammation was observed and
no increased levels of total serum IgE were found (Veh: 221.4
± 66.5 ng/ml vs. TDI: 264.9 ± 105.7 ng/ml) thus confirming the
importance of B-lymphocytes in our model (data not shown).
Second, B-lymphocytes were isolated from the lymph nodes
of TDI-sensitized BALB/c mice and transferred into naïve B-KO
mice. The adoptive transfer of B-lymphocytes now resulted in
airway hyperreactivity after TDI challenge (Figure 3 A),
significant increases in neutrophils and macrophages the BAL
fluid (Figure 3 B), but no increased level of total serum IgE
(Figure 3 C). Histological analysis of these lungs confirmed the
airway inflammation and epithelial damage (Figure 3 D-E).
Third, B-lymphocytes from lymph nodes of TDI-sensitized
mice were transferred into naïve SCID mice. Previously, we
had shown that SCID mice are not able to develop an asthma-
like response after dermal sensitization and challenge with TDI
[15]. However, after transferring B-lymphocytes obtained from
TDI-sensitized mice into naïve SCID mice a significant increase
in airway reactivity (Figure 3 F) and airway inflammation
(Figure 3 G) was found after TDI challenge. The influx of
neutrophils in the lungs was confirmed on histology (Figure 3
H-I).
B-lymphocytes in chemical-induced asthma
PLOS ONE | www.plosone.org 4 December 2013 | Volume 8 | Issue 12 | e83228
Figure 1.  Total serum IgE in donor mice along with surface markers and cytokine production by B-lymphocytes of the
auricular lymph nodes.  Serum and lymphocytes from the auricular lymph nodes were obtained of mice dermally treated with
vehicle (DVeh) or TDI (DTDI). The lymphocytes were stained with anti-CD19 to identify B lineage cells and for different surface markers
and co-stimulatory molecules. CD19+-lymphocytes were co-stained with anti-CD23 and anti-IgD to distinguish between follicular and
marginal zone B-lymphocytes (A); co-stained with CD5 to distinguish between B1- (B1a) and B2-lymphocytes (B) and co-stained
with MHCII, CD86, CD80 and CD40 to characterize the antigen presentation capacity of the B-lymphocytes (C). Lymphocytes of
auricular lymph nodes were cultured in vitro for 5 hours with PMA, Ca2+ ionophore and monensin. Anti-CD19 was used to identify B
lineage cells and the percentage B-lymphocytes staining intracellularly for the cytokines IL-4, IFN-γ and IL-10 was assessed. Figure
1 D shows representative dot plots of intracellular cytokine expression in B-lymphocytes from TDI-sensitized mice. The percentage
of the total B-lymphocytes expressing cytokines is quantified in graph E. In the serum of Dveh or DTDI mice, total IgE levels were
measured (F). Data are presented as means ± SEM, n = 4-5, * p < 0.05 and *** p < 0.001.
doi: 10.1371/journal.pone.0083228.g001
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Figure 2.  Production of an asthma-like response in naïve wild type BALB/c mice after having received B-
lymphocytes.  Experimental groups are DTDIRVeh, DTDIRTDI, DTMARVeh, DTMARTMA and DTDIRTMA. D represents donor (D) animals that
received dermal applications of TDI (DTDI) or TMA (DTMA) on days 1 and 8. Their B-lymphocytes were transferred into naïve recipient
(R) mice which received a challenge with vehicle (RVeh), TDI (RTDI) or TMA (RTMA) three days after the transfer. Airway resistance (R),
after increasing concentrations of methacholine (0-10 mg/ml), was measured using a forced oscillation technique, 22 hours after the
challenge. Figure 2 A reflects the airway hyperreactivity (AHR) to increasing concentrations of methacholine after transferring B-
lymphocytes of auricular lymph nodes into wild type BALB/c mice. Macrophages and neutrophils were identified in the BAL fluid (B)
and in lung tissue (D) 24 hours after the challenge. Total serum IgE was measured (C). Figure 2 E, F, G and H represent AHR of
the experiment assessing the transfer of the B-lymphocytes of TMA sensitized mice, the specificity of the B-lymphocytes to TDI, the
transfer of serum and the transfer of B-lymphocytes of the spleen, respectively. Data are presented mean ± SEM, n = 4-10 per
group, * p < 0.05, ** p < 0.01 and *** p < 0.001 compared with the DTDIRVeh group (A, B, C, G and H) and with DTMARTMA (E).
Symbols: (↑) inflammation and (▲) epithelial damage.
doi: 10.1371/journal.pone.0083228.g002
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Figure 3.  Transferring B-lymphocytes leads to an asthma-like response after TDI challenge in B-KO and SCID BALB/c
mice.  Airway methacholine reactivity was measured after transferring B-lymphocytes in B-KO (A) or SCID (F) mice. Macrophages
and neutrophils were identified in the BAL fluid (B and G) and in lung tissue (D, E and H, I) 24 hours after the challenge. Total IgE
was assessed in serum of B KO mice. Experimental groups for the adoptive transfer setup are identical to those of Figure 2
(DTDIRVeh and DTDIRTDI). Data are presented as means ± SEM, n = 5-8 per group, * p < 0.05, ** p < 0.01, *** p < 0.001
compared to the DTDIRVeh group. Symbols: (↑) inflammation and (▲) epithelial damage.
doi: 10.1371/journal.pone.0083228.g003
B-lymphocytes in chemical-induced asthma
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B-cell homing in the lung after adoptive transfer into
naïve wild type BALB/c mice
In figure 4, freshly isolated and labeled (SNARF-1) B-
lymphocytes obtained from TDI-sensitized mice were
transferred into naïve wild type mice to visualize their presence
in the lung. SNARF-1 positive cells were found close to the
airways of mice challenged with TDI and this was not the case
in mice challenged with vehicle (Figure 4 B-C).
Discussion
We investigated the role of B-lymphocytes in the
development of non-atopic asthma using an established mouse
model of chemical-induced asthma [13–15,18–20]. The main
findings of this study were that B-lymphocytes play an
important role in the induction of AHR and airway inflammation,
even without the presence of T-lymphocytes. Furthermore, B-
lymphocytes of TDI-sensitized mice were shown to produce
cytokines that reflect a mixed Be1-Be2 response and express
surface markers characteristic of antigen presentation capacity.
Studies on B-lymphocytes and their role in the immune
response and more specifically in asthma have almost
exclusively focused on their implication in the humoral
response, i.e. the production of antigen-specific IgE antibodies.
Recently, there has been growing appreciation that B-
lymphocytes also play more central roles in orchestrating
immune responses [23–25]. The role of B-lymphocytes in
cellular immune responses has received renewed interest due
to clinical data showing that B-lymphocyte depletion is an
effective therapy for several T-cell mediated autoimmune
diseases, while the therapy does not necessarily correlate with
changes in the circulating autoantibodies [10]. In low molecular
weight induced asthma, specific IgE antibodies are frequently
not present, which suggests that non-IgE mediated
mechanisms are involved in the pathogenesis [5].
Our data show that transferring B-lymphocytes from TDI-
sensitized mice into naïve wild type mice resulted in an
asthma-like response after a sensitizer-specific challenge. The
protocol for the adoptive transfer of lymphocytes, designed and
optimized previously, is unique because only low,
physiologically relevant, quantities of lymphocytes are sufficient
to obtain the desired response [21]. An amount of only 175,000
B-lymphocytes was enough to passively transfer TDI
sensitization and develop an asthma-like response in naïve
mice after TDI challenge. This is in contrast with other studies
that transfer millions of B-lymphocytes [26–28]. In our
experiment designed to study the homing of B-lymphocyte after
their transfer, we injected a higher quantity, i.e. 5,000,000
labeled B-lymphocytes, in order to increase the chance of
detecting labeled cells in the histological sections of the lung,
and this proved successful.
B-lymphocytes were isolated using CD19+ magnetic beads.
CD19 is a surface glycoprotein expressed by early pre-B-
lymphocytes and throughout B-lymphocyte development, but it
is not present on plasma cells, indicating that no
immunoglobulin producing cells were transferred [29,30]. To
verify this, we transferred serum from TDI-sensitized mice into
wild type naïve mice. Although our data showed limited airway
inflammation and even to a lesser extent AHR after TDI
challenge, this was minor compared to the results obtained
after transferring B-lymphocytes, thus suggesting that
antibodies are not sufficient to induce the response and that
antibody-independent mechanism of B-lymphocytes can lead
to an “allergic” response. This was also confirmed by the fact
that we found no increases in total serum IgE levels in the wild
type mice that received B-lymphocytes. The purity of the
isolated B-lymphocytes was tested several times by FACS. The
combined impurity (CD3+, CD4+, CD8+ and CD25+) was always
less than 5% (data not shown), i.e. fewer than 10,000 cells. We
do admit that the presence of T-lymphocytes and dentritic cells
in this cell population might play a limited role in the response
we find.
In two separate experiments we also tested the specificity of
our response, which represents an essential prerequisite for an
adaptive immune response. In a first experiment we showed
that the DTDIRVeh group (transfer of TDI-sensitized B-
lymphocytes followed by challenge with AOO) and the DVehRTDI
group (transfer of AOO-treated B-lymphocytes followed by
challenge with TDI, data not shown) showed neither increased
AHR nor airway inflammation, the latter group proving (again)
that the response observed after TDI challenge did not simply
result from irritation. In a second experiment, naïve mice were
transferred with TDI-sensitized B-lymphocytes and received a
challenge with trimellitic anhydride, also a known respiratory
sensitizer [14]. These mice showed no AHR and almost no
inflammation in BAL compared to DTDIRTDI mice, suggesting a
TDI-specific asthmatic response triggered by the transferred B-
lymphocytes.
Previously, Lindell et al. showed that B-lymphocytes
contribute to AHR, by using B-KO mice in a cockroach-induced
asthma model. They were the first to provide evidence that
antigen presentation by B-lymphocytes contributes to the
pathogenesis of allergic disease [2]. It has also been
suggested that B-lymphocytes may become increasingly
relevant as antigen presenting cells when antigen load is low
[10]. Our data confirmed the expression of MHCII and co-
stimulatory molecules on the surface of B-lymphocytes of TDI-
sensitized mice thus suggesting a role of antigen presentation
for B-lymphocytes. Furthermore, there are several subsets of
mature B-lymphocytes in the mouse. There are B2-
lymphocytes (follicular and marginal zone B-lymphocytes),
which arise from bone marrow derived precursors and are
enriched in secondary lymphoid organs; on the other hand
there are also B1-lymphocytes (B1a and B1b lymphocytes),
which arise from fetal liver precursors and are enriched in
mucosal tissues and the pleural and peritoneal cavities [31].
Follicular B-lymphocytes participate in the vast majority of
responses against exogenous antigens, while marginal zone
and B1-lymphocytes are characterized by their contribution to
innate-like defense through rapid humoral responses [32]. We
found in the auricular lymph nodes of TDI-sensitized mice
significant increases in follicular B-lymphocytes as well as B1-
lymphocytes, indicating that both subsets are probably
important in the allergic response we find.
The knowledge that CD4+ T-lymphocytes can produce
polarized arrays of cytokines has been extended over the last
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Figure 4.  Transferred B-lymphocytes are present in the lungs of TDI challenged wild type BALB/c mice.  Freshly isolated B-
lymphocytes of the auricular lymph nodes of TDI-sensitized mice were labeled with DAPI and SNARF-1 carboxylic acid acetate and
transferred into naïve wild type BALB/c mice. 5x106 labeled B-lymphocytes were transferred. Three days after the transfer mice
were challenged with TDI and cryostat sections were made. Experimental groups for the adoptive transfer setup are identical to
those of Figure 2 (DTDIRVeh and DTDIRTDI). Figure C shows the merged picture of the DAPI (A) and SNARF-1 (B) staining.
doi: 10.1371/journal.pone.0083228.g004
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years to include CD8+ T-lymphocytes, natural killer cells and
dendritic cells. It is also known that B-lymphocytes are major
producers of a broad range of cytokines, but it was not until
recently that evidence was obtained that B-lymphocytes can be
induced to differentiate into distinct cytokine producing effector
subsets [11,23]. Harris et al. showed in an infection model that
B-lymphocytes have the capacity to produce cytokines such as
IL-2, IFN-γ, IL-12 and IL-4, which have not been traditionally
considered to be B-lymphocyte derived cytokines [11]. B-
lymphocytes of TDI-sensitized mice produced in vitro
substantial amounts of IL-4, IFN-γ or IL-10, suggesting the
presence of Be2 lymphocytes as well as Be1 lymphocytes in
our mouse model. TDI sensitization yields a mixed Th1-Th2
cytokine profile, as previously described by us and other
research groups [15,16,19,33,34]. Our present results show
that probably the same is true for B-lymphocytes. The mixed
cytokine profiles found in chemical-induced asthma are in
contrast with the Th2 prone response found in atopic asthma,
and make it challenging to understand how the development of
this type of asthma is regulated.
To strengthen our results, the adoptive transfer experiments
were repeated in B-KO mice. When we applied our classic
model of dermal sensitization followed by a single airway
challenge with TDI, no asthma-like response was found in B-
KO mice, but this response could be regained after the transfer
of B-lymphocytes. Again, we found no increases in total serum
IgE levels in the B-KO mice that received B-lymphocytes. This
leads us to the conclusion that IgE probably does not play
predominant role in these experiments. Since B-KO mice still
possess T-lymphocytes, and we could not exclude an interplay
between these T-lymphocytes and the transferred B-
lymphocytes, we also performed transfer experiments in SCID
mice which lack both B- and T-lymphocytes. This resulted also
in the induction of an asthma-like response. Apparently, B-
lymphocytes do not need T-lymphocytes to initiate AHR and
airway inflammation in mice. Our study is the first to prove that
B-lymphocytes can solely lead to the development of an
asthma-like response. In isocyanate-induced asthma the
importance of CD4+ and CD8+ T-lymphocytes was already
shown [34,35]. Our study does not imply that B-lymphocytes do
not need T-lymphocytes or other cell types of the immune
system to activate and differentiate during the sensitization
phase, but it does suggest that T-lymphocytes are not
exclusively needed for the effector phase in our model.
Although, B-KO mice have defects in the homeostasis of the
immune system, including fewer T-lymphocytes [25], we are
convinced that the results of the transfer experiments in the B-
KO mice can be interpreted as resulting essentially from their
lack of B-lymphocytes rather than their defective T-
lymphocytes because of the asthma-like responses we
obtained in SCID mice receiving B-lymphocytes.
In conclusion, we have shown that B-lymphocytes play a
crucial role in the development of an asthma-like response in a
mouse model of chemical-induced asthma. Sensitization with
TDI led to a mixed Be1-Be2 cytokine response and transferring
these “sensitized” B-lymphocytes into naïve mice resulted in
AHR and airway inflammation after challenge with TDI.
Furthermore, the generation of a response in SCID mice
suggests that B-lymphocytes can induce an asthmatic
response without the help of T-lymphocytes.
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